The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•24 March 2026•

1 min read

Hoth Therapeutics Reports Positive Clinical Data for HT-001 Cancer Treatment

Key Facts

1Topical HT-001 showed a ~77% increase in drug exposure with minimal systemic absorption.

2Systemic absorption levels were ~99% lower compared to FDA-approved oral formulations.

Hoth Therapeutics (HOTH) announced positive results from its clinical study of HT-001, a topical treatment for skin toxicities in cancer patients undergoing EGFR therapy. The data revealed a significant 77% increase in drug exposure while maintaining minimal systemic absorption. Crucially, systemic levels were approximately 99% lower than those found in FDA-approved oral formulations, significantly reducing potential side effects. No serious adverse events or dose-limiting toxicities were reported during the study, confirming a strong safety profile for the candidate. This milestone validates the company's approach to providing effective local treatment without the risks associated with systemic therapies. Investors view these results as a positive step forward for the company's oncology pipeline and its long-term growth potential.